"Glucosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D005960
|
| MeSH Number(s) |
D09.408.348
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucosides".
Below are MeSH descriptors whose meaning is more specific than "Glucosides".
This graph shows the total number of publications written about "Glucosides" by people in this website by year, and whether "Glucosides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 2 | 5 |
| 2021 | 3 | 4 | 7 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 2 | 1 | 3 |
| 2025 | 3 | 0 | 3 |
| 2026 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucosides" by people in Profiles.
-
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure. Hypertension. 2026 Sep; 83(9):e27036.
-
Empagliflozin-mediated protection of heparan sulfate-rich endothelial glycocalyx during vascular inflammation. Biochem Pharmacol. 2026 Jul; 249:117890.
-
Retinal Ischemia: Therapeutic Effects and Mechanisms of Paeoniflorin. Int J Mol Sci. 2025 Nov 11; 26(22).
-
Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial. Clin Ther. 2025 Dec; 47(12):1091-1096.
-
Use of SGLT2 inhibitors in pediatric heart failure: a multi-center study. Pediatr Cardiol. 2026 Aug; 47(6):2526-2533.
-
Acute Hemodynamic Effects of Empagliflozin: Are They Relevant to the Clinical Practice? Cardiovasc Drugs Ther. 2024 08; 38(4):769-770.
-
Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes. Basic Clin Pharmacol Toxicol. 2024 May; 134(5):643-656.
-
Dapagliflozin for Atrial Fibrillation. Cardiovasc Drugs Ther. 2024 02; 38(1):1-3.
-
Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2025 02; 39(1):43-61.
-
Association Between Change in Ambulatory Pulmonary Artery Pressures and Natriuretic Peptides in Patients with Heart Failure: Results From the EMBRACE-HF Trial. J Card Fail. 2023 09; 29(9):1324-1328.